Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
59
Frequently Asked Questions
What is Altimmune Inc stock price today?
Altimmune Inc stock price today is $12.85.
What was Altimmune Inc stock price yesterday?
Altimmune Inc stock price yesterday was $13.34.
What is Altimmune Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Altimmune Inc's EBITDA is -5.54.